Company Profile

Spring Bank Pharmaceuticals Inc (AKA: Spring Bank Technologies Inc~SBT)
Profile last edited on: 12/4/17      CAGE: 4G9W1      UEI:

Business Identifier: Small-molecule nucleic acid hybrid chemistry platform
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

113 Cedar Street Suite S-7
Milford, MA 01757
   (508) 473-5993
Location: Single
Congr. District: 04
County: Worcester

Public Profile

Spring Bank Pharmaceuticals is a clinical stage drug discovery company. Based on a proprietary platform technology, the firm is developing a pipeline of products representing a new class of pharmaceuticals called small molecule nucleic acid hybrids “SMNH,” with a wide range of applications and multi-billion dollar market potential. These rationally designed molecules combine the selectivity of naturally occurring nucleotides, with the drug like properties of classical pharmaceuticals. These SMNHs have the properties of oral delivery, good pharmacokinetics, low side effects and ease of manufacture. The firm's most advanced product is SB 9200, a potential breakthrough drug for Hepatitis B and C, works by up-regulating the host immune response in the presence of viral infection. Clinical studies for SB 9200 began in early 2013. The firm has a robust pre-clinical pipeline behind SB 9200 with programs in Respiratory Syncytial Virus (RSV), a Broad Spectrum Antiviral and an earlier stage research program for CO

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2010 2 NIH $600,000
Project Title: Dinucleotide Isomer As A Novel Antiviral

Key People / Management

  Martin J Driscoll -- Chairman, CEO and President

  Douglas J Jensen -- Co-Founder, President and CEO

  Ramakrishna Iyer -- Co-Founder, Chief Scientific Officer

  Don Mitchell -- VP of Operations and Corporate Development